Browse by Audience
MEMBER

Update Your Profile
Member Spotlights
Refer a Member: IASP Champions
Join a Special Interest Group (SIG)
Find a Chapter
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Papers of the Week
Webinars and Podcasts
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Webinars & Podcasts
Curricula
Graduate Opportunities
Events

PATIENT & CAREGIVER

RELIEF News
Resources for Living with Pain
Global Alliance of Partners in Pain Advocacy (GAPPA)
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner

gy2022-1-3
I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / Efficacy and safety of vebicorvir administered in virologically-suppressed patients with chronic hepatitis B virus infection.

< BACK TO ARCHIVE


2022 Apr 20


J Hepatol


http://www.ncbi.nlm.nih.gov/pubmed/35460726?dopt=Abstract

Efficacy and safety of vebicorvir administered in virologically-suppressed patients with chronic hepatitis B virus infection.

Authors

Efficacy and safety of vebicorvir administered in virologically-suppressed patients with chronic hepatitis B virus infection.
Yuen M-F, Agarwal K, Ma X, Nguyen TT, Schiff ER, Hann H-WL, Dieterich DT, Nahass RG, Park JS, Chan S, Han S-HB, Gane EJ, Bennett M, Alves K, Evanchik M, Yan R, Huang Q, Lopatin U, Colonno R, Ma J, et al.
J Hepatol. 2022 Apr 20.
PMID: 35460726.

Abstract

Hepatitis B virus (HBV) nucleos(t)ide reverse transcriptase inhibitors (NrtI) do not completely suppress HBV replication. Previous reports indicate persistent viremia during NrtI treatment despite HBV DNA being undetectable. HBV core inhibitors may enhance viral suppression when combined with NrtIs. This phase 2 trial (NCT03576066) evaluated the efficacy and safety of the investigational core inhibitor, vebicorvir (VBR), in virologically-suppressed patients on NrtI.
Read This Paper